retatrutide triple hormone receptor agonist metabolic obesity may represent the most aggressive peptide studied to date. Unlike single GLP 1 agonists, it activates GLP 1, GIP, & glucagon receptors simultaneously — suppressing appetite while increasing energy Retatrutide Severe Obesity Trial Shows
Pay in 4 interest-free payments of $6.15 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




























